SCHEMBL19976729

SCHEMBL19976729

CC(C)CN/C(=N/C(=O)c1ccc(Cl)c(F)c1)Nc1n[nH]c2cc(C(F)(F)F)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 8/20 0.49
GSK3B P49841 2/20 0.48
TRPA1 O75762 3/20 0.40
MAPK1 P28482 3/20 0.40
MAP2K4 P45985 1/20 0.40
MAPK6 Q16659 1/20 0.40
MAPKAPK5 Q8IW41 1/20 0.40
ABL1 P00519 1/20 0.38
BCR P11274 1/20 0.38
SRC P12931 1/20 0.38
MAPK14 Q16539 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
KCNQ3 O43525 1/20 0.38
KCNQ2 O43526 1/20 0.38
KCNQ1 P51787 1/20 0.38
SCN5A Q14524 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19976767 0.93 GSK3B (0.51) HDAC6GSK3BTRPA1MAPK1MAP2K4
SCHEMBL19976829 0.89 HDAC6 (0.51) HDAC6GSK3BTRPA1MAPK1MAP2K4
SCHEMBL19976754 0.86 HDAC6 (0.52) HDAC6GSK3BTRPA1MAPK1MAP2K4
SCHEMBL19976907 0.86 GSK3B (0.49) HDAC6GSK3BTRPA1MAPK1MAP2K4
SCHEMBL19976854 0.86 GSK3B (0.42) HDAC6GSK3BTRPA1MAPK1MAP2K4
SCHEMBL19976733 0.85 HDAC6 (0.47) HDAC6GSK3BTRPA1MAPK1MAP2K4
SCHEMBL19976776 0.85 GSK3B (0.48) HDAC6GSK3BTRPA1MAPK1MAP2K4
SCHEMBL19976753 0.84 GSK3B (0.47) HDAC6GSK3BTRPA1MAPK1MAP2K4
SCHEMBL19976789 0.84 GSK3B (0.42) HDAC6GSK3BMAPK1
SCHEMBL19976752 0.82 HDAC6 (0.49) HDAC6GSK3BTRPA1MAPK1MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920012-B2 Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-03-20 US disclosed